Intercept Pharmaceuticals increases deal size, prices IPO at $15, at high end of the range

By
A A A

Intercept Pharmaceuticals, which is developing novel synthetic therapeutics for chronic liver diseases, raised $75 million by offering 5.0 million shares at $15, at high end of the range of $13 to $15. The company was able to raise an additional $11 million by offering an additional 700,000 shares. Intercept Pharmaceuticals plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch acted as the lead bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ICPT

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

My Career No Longer Exists
My Career No Longer Exists          

Stocks

Referenced

Most Active by Volume

105,767,201
  • $46.30 ▲ 19.98%
80,574,036
  • $15.58 ▲ 1.56%
66,424,299
  • $3.46 ▲ 1.76%
42,459,394
  • $3.82 ▲ 0.79%
36,704,800
  • $13.98 ▼ 14.02%
35,625,113
  • $74.677 ▲ 1.31%
33,067,430
  • $29.26 ▼ 0.71%
32,374,580
  • $98.15 ▼ 0.23%
As of 7/30/2014, 04:04 PM